Skip to main content
. Author manuscript; available in PMC: 2017 Dec 6.
Published in final edited form as: Cell Rep. 2016 Dec 6;17(10):2503–2511. doi: 10.1016/j.celrep.2016.11.020

Figure 1. Relative Timing of Combination Immunotherapy Component Administration Determines Synergistic Antitumor Efficacy and Requires Specific Elements of Innate and Adaptive Immunity.

Figure 1

(A) Survival curves for mice injected s.c. with 106 B16F10 melanoma cells, then treated on days 6 and 12 with PBS or FcIL2 + TA99. Mice given FcIL2 + TA99 also received IFNα at indicated time points relative to FcIL2 + TA99 treatment. n = 5–9 per group.

(B) Survival curves for mice treated as described in (A), or with one of the three therapeutic components omitted. n = 5–13 per group.

(C) Survival curves for mice treated as described in (A). Mice given immunotherapy were also injected with the indicated depleting or neutralizing antibodies. n = 8–15 per group.

(D) Survival curves for wild-type or Batf3−/− mice treated as described in (A). n = 5–10 per group.

(E) MFI levels of CD86 expression by draining lymph node CD8α+ DCs (CD3−CD11chiPDCA-1−CD8α+) from immunotherapy-treated mice bearing established s.c. B16F10 tumors. n = 4–5 per group.

(F) Percentages of draining lymph node or intratumoral CD8+ T cells expressing CD69 or CD25. Cells were isolated from immunotherapy-treated mice bearing established s.c. B16F10 tumors. n = 4–5 per group.

Data represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 between the indicated pairs or versus the corresponding color group in the legend. See also Figures S1 and S2.